Key Points
- CFO Christine Marie Plummer sold 10,922 shares on April 13 at an average of $1.10 for $12,014.20 (and an additional 2,581 shares on April 15 for $2,787.48) to cover tax withholding from vested equity; she now directly owns 489,078 shares, a 2.18% reduction in her stake.
- Biosig Technologies (STEX) trades near $1.11 (50‑day MA $1.78) with a one‑year range of $0.49–$14.11 and a market cap of about $201M, reported quarterly EPS of ($8.23), and has mixed analyst coverage with a consensus "Hold" and a $9.00 price target.
Biosig Technologies, Inc. (NASDAQ:STEX - Get Free Report) CFO Christine Marie Plummer sold 10,922 shares of the company's stock in a transaction dated Monday, April 13th. The stock was sold at an average price of $1.10, for a total transaction of $12,014.20. Following the sale, the chief financial officer directly owned 489,078 shares in the company, valued at $537,985.80. This represents a 2.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Christine Marie Plummer also recently made the following trade(s):
- On Wednesday, April 15th, Christine Marie Plummer sold 2,581 shares of Biosig Technologies stock. The shares were sold at an average price of $1.08, for a total transaction of $2,787.48.
Biosig Technologies Price Performance
STEX opened at $1.11 on Friday. Biosig Technologies, Inc. has a one year low of $0.49 and a one year high of $14.11. The firm's 50 day moving average is $1.78. The company has a market capitalization of $201.07 million, a PE ratio of -0.12 and a beta of 1.90.
Biosig Technologies (NASDAQ:STEX - Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($8.23) EPS for the quarter.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on STEX. Needham & Company LLC decreased their price target on shares of Biosig Technologies from $12.00 to $9.00 and set a "buy" rating on the stock in a research note on Thursday, April 9th. Weiss Ratings started coverage on shares of Biosig Technologies in a research note on Friday, January 23rd. They issued a "sell (d-)" rating on the stock. Finally, Wall Street Zen cut shares of Biosig Technologies from a "hold" rating to a "strong sell" rating in a research note on Sunday, April 5th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $9.00.
View Our Latest Stock Analysis on Biosig Technologies
Biosig Technologies Company Profile
(
Get Free Report)
Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.
Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
